WO2015186144A3 - Procédé d'inhibition de la bêta-sécrétase au moyen de bis-o-déméthylcurcumine pour la prévention, la prise en charge et le traitement de maladies neurodégénératives - Google Patents

Procédé d'inhibition de la bêta-sécrétase au moyen de bis-o-déméthylcurcumine pour la prévention, la prise en charge et le traitement de maladies neurodégénératives Download PDF

Info

Publication number
WO2015186144A3
WO2015186144A3 PCT/IN2015/000232 IN2015000232W WO2015186144A3 WO 2015186144 A3 WO2015186144 A3 WO 2015186144A3 IN 2015000232 W IN2015000232 W IN 2015000232W WO 2015186144 A3 WO2015186144 A3 WO 2015186144A3
Authority
WO
WIPO (PCT)
Prior art keywords
demethylcurcumin
bis
beta
secretase
inhibition
Prior art date
Application number
PCT/IN2015/000232
Other languages
English (en)
Other versions
WO2015186144A2 (fr
Inventor
Ganga Raju Gokaraju
Rama Raju Gokaraju
Trimurtulu Golakoti
Venkateswarlu Somepalli
Kiran Bhupathiraju
Ramchand Nanappan Chaniyilparampu
Nirvanashetty Somashekara
Original Assignee
Laila Pharmaceuticals Pvt. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laila Pharmaceuticals Pvt. Ltd. filed Critical Laila Pharmaceuticals Pvt. Ltd.
Publication of WO2015186144A2 publication Critical patent/WO2015186144A2/fr
Publication of WO2015186144A3 publication Critical patent/WO2015186144A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un nouveau procédé d'inhibition de l'enzyme bêta-sécrétase au moyen de bis-o-déméthylcurcumine. L'invention porte en outre sur la prévention, la prise en charge et le traitement de la maladie d'Alzheimer par l'inhibition de la bêta-sécrétase chez un patient au moyen de bis-o-déméthylcurcumine. L'invention a également trait au processus de synthèse de bis-o-déméthylcurcumine et à des compositions les comprenant.
PCT/IN2015/000232 2014-06-07 2015-06-05 Procédé d'inhibition de la bêta-sécrétase au moyen de bis-o-déméthylcurcumine pour la prévention, la prise en charge et le traitement de maladies neurodégénératives WO2015186144A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2800CH2014 2014-06-07
IN2800/CHE/2014 2014-06-07

Publications (2)

Publication Number Publication Date
WO2015186144A2 WO2015186144A2 (fr) 2015-12-10
WO2015186144A3 true WO2015186144A3 (fr) 2016-01-28

Family

ID=54767524

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2015/000232 WO2015186144A2 (fr) 2014-06-07 2015-06-05 Procédé d'inhibition de la bêta-sécrétase au moyen de bis-o-déméthylcurcumine pour la prévention, la prise en charge et le traitement de maladies neurodégénératives

Country Status (1)

Country Link
WO (1) WO2015186144A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109172538A (zh) * 2018-10-25 2019-01-11 安徽鼎旺医药有限公司 一种盐酸美金刚速溶微丸软胶囊

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080138400A1 (en) * 2004-03-05 2008-06-12 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of diseases
US20090324703A1 (en) * 2006-03-06 2009-12-31 Frautschy Sally A Bioavailable curcuminoid formulations for treating alzheimer's disease and other age-related disorders
US20110112190A1 (en) * 2008-07-07 2011-05-12 Laila Pharmaceuticals Pvt. Ltd. Orally active curcuminoid compounds
US8021701B1 (en) * 2005-04-13 2011-09-20 Perry Stephen C Composition to retard the onset of symptoms of alzheimer's disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080138400A1 (en) * 2004-03-05 2008-06-12 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of diseases
US8021701B1 (en) * 2005-04-13 2011-09-20 Perry Stephen C Composition to retard the onset of symptoms of alzheimer's disease
US20090324703A1 (en) * 2006-03-06 2009-12-31 Frautschy Sally A Bioavailable curcuminoid formulations for treating alzheimer's disease and other age-related disorders
US20110112190A1 (en) * 2008-07-07 2011-05-12 Laila Pharmaceuticals Pvt. Ltd. Orally active curcuminoid compounds

Also Published As

Publication number Publication date
WO2015186144A2 (fr) 2015-12-10

Similar Documents

Publication Publication Date Title
WO2016130920A3 (fr) Inhibiteurs de lrrk2 et leurs méthodes de production et d'utilisation
EP3140403A4 (fr) Prévention et traitement de la maladie d'alzheimer par édition du génome à l'aide du système crispr/cas
EP3675859A4 (fr) Composés, compositions et méthodes pour le traitement d'une maladie
WO2015148863A3 (fr) Méthodes liées à crispr/cas et compositions pour le traitement de la drépanocytose
NZ735044A (en) Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof
WO2013033037A3 (fr) Nouveaux composés d'antiprion
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
WO2018023072A3 (fr) Composés et compositions, et utilisations associées
NZ760749A (en) Bicyclic ketone compounds and methods of use thereof
MX2024009894A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
WO2016004413A3 (fr) Inhibiteurs de la gls1 pour le traitement de maladies
WO2016004404A3 (fr) Inhibiteurs de gls1 utiles pour le traitement de maladies
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
PH12019500198A1 (en) Compounds and compositions and uses thereof
WO2015195950A8 (fr) Inhibiteurs de lmp7
WO2017044807A3 (fr) Réduction du fragment c99 de l'app localisé sur la membrane er-mam et procédés de traitement de la maladie d'alzheimer
IL270927B (en) fused 5,6 bicyclic compounds and compounds for the treatment of parasitic diseases
EP3746057A4 (fr) Procédé de prévention ou de traitement de la maladie d'alzheimer
AU2015280874A1 (en) Novel heterocyclic compound
MX2016008968A (es) Compuestos organicos.
TN2017000448A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer's disease
EP3820477A4 (fr) Composés, compositions et procédés pour le traitement d'une maladie
WO2016069542A3 (fr) Composés de lactone, leurs procédés de préparation et d'utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15803805

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15803805

Country of ref document: EP

Kind code of ref document: A2